<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00872729</url>
  </required_header>
  <id_info>
    <org_study_id>RP103-01</org_study_id>
    <nct_id>NCT00872729</nct_id>
  </id_info>
  <brief_title>Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis</brief_title>
  <official_title>A Pilot Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cysteamine Bitartrate (Cystagon®) in Patients With Nephropathic Cystinosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Horizon Pharma USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Horizon Pharma USA, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cystinosis is an inheritable disease that if untreated, results in kidney failure as early as
      the first decade of life. The current marketed therapy is Cystagon® (cysteamine bitartrate)
      which must be taken every six hours for the rest of the patient's life to prevent
      complications of cystinosis. RP103 is a formulation of cysteamine bitartrate that is being
      studied to see if it may be able to be given less frequently, once every 12 hours, and have
      similar results.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-dose, open-labeled, non-randomized, two-period study of Cysteamine
      Bitartrate Delayed-release Capsules (RP103) and Cystagon® in up to 10 patients (male or
      female) with nephropathic cystinosis under fasting conditions. It will involve a 4 night
      check-in to a clinical research center.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Pharmacokinetic Parameter: Cmax of Cysteamine</measure>
    <time_frame>12 hours post RP103 dosing and 7 hours post 1st Cystagon® dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Pharmacokinetic Parameter: Tmax of Cysteamine</measure>
    <time_frame>12 hours post RP103 dosing and 7 hours post 1st Cystagon® dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Pharmacokinetic Parameter: AUC(0-t) of Cysteamine</measure>
    <time_frame>12 hours post RP103 dosing and 6 hours post 1st Cystagon® dosing</time_frame>
    <description>t = 6 for Cystagon and t = 12 for RP103. Cystagon is dosed every 6 hours and there is no measurement after 6 hours and up to 12 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic Parameter: Changes of White Blood Cell (WBC) Cystine Level From Baseline</measure>
    <time_frame>up to 12 hours post Cystagon® dosing and RP103 dosing</time_frame>
    <description>The pharmacodynamic (PD) parameter measures the changes of WBC cystine level from the baseline.
Cystine is a disulfide amino acid formed through oxidation of two molecules of cysteine; hence, cystine's concentration is commonly given in half-cystine equivalents to avoid confusion.
The level of cystine in WBC/leukocytes is expressed in units of nmol half-cystine/mg protein (nmol ½ cystine/mg protein). Half-cystine is quantified by a reduction of cystine followed by an assay for cysteine, which is then normalized by the total cellular protein content within the sample using methods of such as Lowry assay, bicinchoninic acid assay, or Bradford.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Cystinosis</condition>
  <arm_group>
    <arm_group_label>Cystagon®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RP103</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cystagon®</intervention_name>
    <description>Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.
Duration of Treatment and Dose: Reference Period up to four doses Q6H.</description>
    <arm_group_label>Cystagon®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RP103</intervention_name>
    <description>Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.
Duration of treatment and Dose: Single dose of Test Product at dose equivalent to Reference Product.</description>
    <arm_group_label>RP103</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects must have nephropathic cystinosis.

          -  Children less than 22.5 kg will only be included in the study if the investigator
             feels they can safely participate in the study including the required blood draw
             volume for the safety and PK/PD assessments.

          -  Subjects must be on a stable dose of Cystagon® at least 21 days prior to Screening.

          -  Subjects must be able to swallow a 150 mg Cystagon® capsule with the capsule intact.

          -  Within the last 2 months, no clinically significant change in liver function [i.e.,
             ALT, AST, alkaline phosphatase, bilirubin (total and direct)] and renal function
             [i.e., serum creatinine, albumin, total protein] at Screening as determined by the
             Investigator.

          -  Sexually active female subjects of childbearing potential (i.e., not surgically
             sterile [tubal ligation, hysterectomy, or bilateral oophorectomy] or at least 2 years
             naturally postmenopausal) must agree to utilize the same acceptable form of
             contraception from screening through completion of the study.

          -  Subjects or their authorized caregiver must provide written informed consent and
             assent (where applicable) prior to participation in the study.

          -  If in the opinion of the investigator, patients can safely provide the study required
             blood draw volume.

          -  Subjects must be willing and able to comply with the study restrictions and
             requirements.

        Exclusion Criteria:

          -  If, in the opinion of the investigator, the planned study dose would exceed the
             patient's tolerability of cysteamine based on their prior Cystagon® steady state drug
             requirements.

          -  Evidence of or verbal attestation of Helicobacter pylori infection, presently, or
             within the last 90 days prior to Screening.

          -  Subjects with a known history, currently or within the past 90 days prior to
             Screening, of the following conditions or other health issues that make it, in the
             opinion of the investigator, unsafe for them to participate, or whose concomitant
             medical problems preclude them from committing to the study schedule including the
             following: Crohn's disease, inflammatory bowel disease (if currently active) or have
             had prior resection of small intestine; • History of heart disease, e.g., myocardial
             infarction, heart failure, arrhythmias; Any bleeding disorder; Malignant disease;
             Severe liver disease as defined as ALT or AST &gt; 2 times the upper limit of normal.

          -  Subjects who have had a kidney transplant.

          -  Subjects who are planning or are a registered candidate for a kidney transplant within
             3 months of the Screening or have a serum creatinine &gt; 2.4.

          -  Subjects with known hypersensitivity to cysteamine.

          -  If female (of child-bearing potential), are nursing, planning a pregnancy, known or
             suspected to be pregnant, or have a positive urine pregnancy screen.

          -  Patients with a hemoglobin level &lt; 10.5.

          -  Subjects who have a made a blood donation within 60 days prior to study initiation.

          -  Subjects who, in the opinion of the Investigator, are not able or willing to comply
             with the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evelyn Olson, BS</last_name>
    <role>Study Director</role>
    <affiliation>Horizon Pharma USA, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Diego Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.procysbi.com</url>
    <description>RP103 (marketed as PROCYSBI) is now approved by the US FDA for management of nephropathic cystinosis in patients 6 years and older</description>
  </link>
  <link>
    <url>http://biochemgen.ucsd.edu/Cystinosis/Index.htm</url>
    <description>Click here for more information about UCSD's cystinosis program</description>
  </link>
  <reference>
    <citation>Dohil R, Fidler M, Barshop BA, Gangoiti J, Deutsch R, Martin M, Schneider JA. Understanding intestinal cysteamine bitartrate absorption. J Pediatr. 2006 Jun;148(6):764-9.</citation>
    <PMID>16769383</PMID>
  </reference>
  <reference>
    <citation>Fidler MC, Barshop BA, Gangoiti JA, Deutsch R, Martin M, Schneider JA, Dohil R. Pharmacokinetics of cysteamine bitartrate following gastrointestinal infusion. Br J Clin Pharmacol. 2007 Jan;63(1):36-40.</citation>
    <PMID>17229040</PMID>
  </reference>
  <reference>
    <citation>Levtchenko EN, van Dael CM, de Graaf-Hess AC, Wilmer MJ, van den Heuvel LP, Monnens LA, Blom HJ. Strict cysteamine dose regimen is required to prevent nocturnal cystine accumulation in cystinosis. Pediatr Nephrol. 2006 Jan;21(1):110-3. Epub 2005 Oct 27.</citation>
    <PMID>16252107</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2009</study_first_submitted>
  <study_first_submitted_qc>March 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2009</study_first_posted>
  <results_first_submitted>October 5, 2012</results_first_submitted>
  <results_first_submitted_qc>October 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 28, 2014</results_first_posted>
  <last_update_submitted>April 11, 2017</last_update_submitted>
  <last_update_submitted_qc>April 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cystinosis</keyword>
  <keyword>cysteamine</keyword>
  <keyword>inheritable disease</keyword>
  <keyword>orphan disease</keyword>
  <keyword>CTNS protein, human</keyword>
  <keyword>nephropathic cystinosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystinosis</mesh_term>
    <mesh_term>Fanconi Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cysteamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cystagon® and RP103</title>
          <description>Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules,150 mg/50 mg; Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules,75 mg; Single-dose, open-label, nonrandomized, 2-period, crossover study of cysteamine bitartrate delayed-release capsules (RP103) and Cystagon®. Subjects were enrolled sequentially and received Cystagon® first followed by RP103.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cystagon® and RP103</title>
          <description>Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules,150 mg/50 mg; Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules,75 mg.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.8" spread="4.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Pharmacokinetic Parameter: Cmax of Cysteamine</title>
        <time_frame>12 hours post RP103 dosing and 7 hours post 1st Cystagon® dosing</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cystagon®</title>
            <description>Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.</description>
          </group>
          <group group_id="O2">
            <title>RP103</title>
            <description>Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetic Parameter: Cmax of Cysteamine</title>
          <units>umol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.02" spread="51"/>
                    <measurement group_id="O2" value="33.06" spread="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Pharmacokinetic Parameter: Tmax of Cysteamine</title>
        <time_frame>12 hours post RP103 dosing and 7 hours post 1st Cystagon® dosing</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cystagon®</title>
            <description>Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.</description>
          </group>
          <group group_id="O2">
            <title>RP103</title>
            <description>Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetic Parameter: Tmax of Cysteamine</title>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O2" value="3.00" lower_limit="0.00" upper_limit="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Pharmacokinetic Parameter: AUC(0-t) of Cysteamine</title>
        <description>t = 6 for Cystagon and t = 12 for RP103. Cystagon is dosed every 6 hours and there is no measurement after 6 hours and up to 12 hours.</description>
        <time_frame>12 hours post RP103 dosing and 6 hours post 1st Cystagon® dosing</time_frame>
        <population>Subjects were enrolled sequentially according to the study design. A mixed-effects linear model was used to assess differences between the RP103 and Cystagon treatment groups. Sample size is based on feasibility rather than statistical considerations.</population>
        <group_list>
          <group group_id="O1">
            <title>Cystagon®</title>
            <description>Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.</description>
          </group>
          <group group_id="O2">
            <title>RP103</title>
            <description>Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetic Parameter: AUC(0-t) of Cysteamine</title>
          <description>t = 6 for Cystagon and t = 12 for RP103. Cystagon is dosed every 6 hours and there is no measurement after 6 hours and up to 12 hours.</description>
          <population>Subjects were enrolled sequentially according to the study design. A mixed-effects linear model was used to assess differences between the RP103 and Cystagon treatment groups. Sample size is based on feasibility rather than statistical considerations.</population>
          <units>umol•h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.89" spread="58"/>
                    <measurement group_id="O2" value="119.17" spread="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacodynamic Parameter: Changes of White Blood Cell (WBC) Cystine Level From Baseline</title>
        <description>The pharmacodynamic (PD) parameter measures the changes of WBC cystine level from the baseline.
Cystine is a disulfide amino acid formed through oxidation of two molecules of cysteine; hence, cystine’s concentration is commonly given in half-cystine equivalents to avoid confusion.
The level of cystine in WBC/leukocytes is expressed in units of nmol half-cystine/mg protein (nmol ½ cystine/mg protein). Half-cystine is quantified by a reduction of cystine followed by an assay for cysteine, which is then normalized by the total cellular protein content within the sample using methods of such as Lowry assay, bicinchoninic acid assay, or Bradford.</description>
        <time_frame>up to 12 hours post Cystagon® dosing and RP103 dosing</time_frame>
        <population>Sample size is based on feasibility rather than statistical considerations. Analysis time differences (0-6 hours) is due to different absorption characteristics of Cysteamine between RP103 and Cystagon. Cystagon is dosed every 6 hours and there is no measurement after 6 hours and up to 12 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Cystagon® (0.5 Hour)</title>
            <description>Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.</description>
          </group>
          <group group_id="O2">
            <title>RP103 (0.5 Hour)</title>
            <description>Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.</description>
          </group>
          <group group_id="O3">
            <title>Cystagon® (1 Hour)</title>
            <description>Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.</description>
          </group>
          <group group_id="O4">
            <title>RP103 (1 Hour)</title>
            <description>Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.</description>
          </group>
          <group group_id="O5">
            <title>Cystagon® (2 Hour)</title>
            <description>Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.</description>
          </group>
          <group group_id="O6">
            <title>RP103 (2 Hour)</title>
            <description>Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.</description>
          </group>
          <group group_id="O7">
            <title>Cystagon® (2.5 Hour)</title>
            <description>Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.</description>
          </group>
          <group group_id="O8">
            <title>RP103 (2.5 Hour)</title>
            <description>Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.</description>
          </group>
          <group group_id="O9">
            <title>Cystagon® (3 Hour)</title>
            <description>Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.</description>
          </group>
          <group group_id="O10">
            <title>RP103 (3 Hour)</title>
            <description>Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.</description>
          </group>
          <group group_id="O11">
            <title>Cystagon® (4 Hour)</title>
            <description>Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.</description>
          </group>
          <group group_id="O12">
            <title>RP103 (4 Hour)</title>
            <description>Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.</description>
          </group>
          <group group_id="O13">
            <title>Cystagon® (6 Hour)</title>
            <description>Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.</description>
          </group>
          <group group_id="O14">
            <title>RP103 (6 Hour)</title>
            <description>Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.</description>
          </group>
          <group group_id="O15">
            <title>Cystagon® (8 Hour)</title>
            <description>Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.</description>
          </group>
          <group group_id="O16">
            <title>RP103 (8 Hour)</title>
            <description>Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.</description>
          </group>
          <group group_id="O17">
            <title>Cystagon® (10 Hour)</title>
            <description>Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.</description>
          </group>
          <group group_id="O18">
            <title>RP103 (10 Hour)</title>
            <description>Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.</description>
          </group>
          <group group_id="O19">
            <title>Cystagon® (12 Hour)</title>
            <description>Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.</description>
          </group>
          <group group_id="O20">
            <title>RP103 (12 Hour)</title>
            <description>Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Parameter: Changes of White Blood Cell (WBC) Cystine Level From Baseline</title>
          <description>The pharmacodynamic (PD) parameter measures the changes of WBC cystine level from the baseline.
Cystine is a disulfide amino acid formed through oxidation of two molecules of cysteine; hence, cystine’s concentration is commonly given in half-cystine equivalents to avoid confusion.
The level of cystine in WBC/leukocytes is expressed in units of nmol half-cystine/mg protein (nmol ½ cystine/mg protein). Half-cystine is quantified by a reduction of cystine followed by an assay for cysteine, which is then normalized by the total cellular protein content within the sample using methods of such as Lowry assay, bicinchoninic acid assay, or Bradford.</description>
          <population>Sample size is based on feasibility rather than statistical considerations. Analysis time differences (0-6 hours) is due to different absorption characteristics of Cysteamine between RP103 and Cystagon. Cystagon is dosed every 6 hours and there is no measurement after 6 hours and up to 12 hours.</population>
          <units>nmol 1/2 cystine/mg protein</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="9"/>
                <count group_id="O14" value="6"/>
                <count group_id="O15" value="0"/>
                <count group_id="O16" value="3"/>
                <count group_id="O17" value="0"/>
                <count group_id="O18" value="3"/>
                <count group_id="O19" value="3"/>
                <count group_id="O20" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.24"/>
                    <measurement group_id="O3" value="-0.10" spread="0.02"/>
                    <measurement group_id="O4" value="0.87" spread="0.33"/>
                    <measurement group_id="O5" value="-0.07" spread="0.28"/>
                    <measurement group_id="O8" value="0.19" spread="0.48"/>
                    <measurement group_id="O9" value="-0.14" spread="0.06"/>
                    <measurement group_id="O10" value="0.43" spread="0.70"/>
                    <measurement group_id="O11" value="-0.01" spread="0.15"/>
                    <measurement group_id="O12" value="0.10" spread="0.50"/>
                    <measurement group_id="O13" value="0.30" spread="0.34"/>
                    <measurement group_id="O14" value="0.22" spread="0.41"/>
                    <measurement group_id="O16" value="0.20" spread="0.31"/>
                    <measurement group_id="O18" value="0.45" spread="0.36"/>
                    <measurement group_id="O19" value="0.37" spread="0.18"/>
                    <measurement group_id="O20" value="0.72" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>After a dose of study drug (RP103 or Cystagon®) on or after study entry, for up to 10 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cystagon®</title>
          <description>Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg;</description>
        </group>
        <group group_id="E2">
          <title>RP103</title>
          <description>Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 11.1">Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Breath odor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin odour abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators may publish or disclose study data, with the restriction that sponsor may embargo such communications for a period up to 60 days from the time submitted to sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Evelyn Olson, Director</name_or_title>
      <organization>Horizon Orphan LLC</organization>
      <phone>224-383-3000</phone>
      <email>clinicaltrials@horizonpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

